At the nexus of commercial success and non-obviousness
Dr. Gregory K. Bell recently testified in three successful challenges to abbreviated new drug applications (ANDA) on behalf of pharmaceutical manufacturers...
Cavay Ip provides expertise in commercialization strategy and pricing and market access strategy to help pharmaceutical and biotech clients achieve their financial and operational goals.
Mr. Ip has developed strategies to launch several market-leading treatments in oncology, immunology, cardiology, and several rare diseases in the U.S. and globally. He has partnered with clients from preclinical/development stage to commercial manufacturers on strategies that help realize the value of their assets and investments.
Mr. Ip also provides financial analysis and valuation assessments in antitrust, litigation, and commercial disputes. In the life sciences industry, he has assessed damages and liability in commercial disputes, intellectual property infringement, and trade secrets misappropriation matters. Beyond the life sciences, Mr. Ip has supported clients with commercial disputes and valuation and financial reporting matters across a range of industries, including technology, nuclear energy, oil and gas, hospitals, airline, retail and consumer products, and the pulp and paper industries.